Shorter HCV Treatment Effective
Posted on: Thursday, 3 January 2008, 15:00 CST
Two randomized controlled trials in Italy and Norway show that treating Hepatitis C for shorter durations can be effective for some patients.
Researchers led by Alessandra Mangia of Italy's Istituto di Ricovero e Cura a Carattere Scientifico, Casa Sollievo Della Sofferenza, in San Giovanni Rotondo, Italy, conducted a randomized controlled trial of 696 patients with HCV genotype 1.
Of the 696 patients, 237 received standard HCV treatment and the remaining 459 were treated for 24, 48 or 72 weeks. A majority of patients who showed a viral response at Week 4 were cured by a 24-week therapy, however, for patients who didn't show a response until Week 12, 72 weeks of treatment was required for an approximately similar cure rate.
Researchers in Norway led by Olav Dalgard conducted a randomized controlled trial of 428 patients with HCV genotype 2 or 3 to assess the success rate of 14 weeks of treatment with the drugs peginterferon and ribavirin -- for 14 or 24 weeks.
The researchers found that 81 percent of patients in the 14-week treatment group achieved a sustained viral response, with 86 percent still cured at 24-weeks post-treatment.
The findings are published in the journal Hepatology.
Source: United Press International
Related Articles
- Marshfield Clinic Selects SAP(R) BusinessObjects(TM) Solutions to Improve Patient Treatment and Clinic Management
- Valeant Pharmaceuticals Reports Encouraging Phase IIb Results at Treatment Week 12 for Taribavirin
- Oculus Completes Patient Treatment in Phase II Diabetic Foot Ulcer Trial
- Oculus Innovative Sciences Completes Patient Treatment and Follow-Up in Its Phase II Clinical Trial in Mildly Infected Diabetic Foot Ulcers
- Patient Treatment for Bipolar Disorder Varies Depending on Doctor Specialty; Well Designed Clinical Trials May Be The Answer
- USNS Comfort Conducts 55,465 Patient Treatments in First Month
- NRC+Picker Highlights Safe Medication Administration During National Patient Safety Week
- Viventia Initiates Patient Treatment in Bladder Cancer Trial
- Work Starts on ASH's List of Repairs: Recent Analysis Showed Breakdowns in Patient Treatment
- ImClone Systems Commences Patient Treatment in U.S. Phase I Clinical Trial Of IMC-1121B
 |
 |
User Comments (0)
RSS Feeds